Hitsumoto Takashi
Hitsumoto Medical Clinic, 2-7-7, Takezakicyou, Shimonoseki City, Yamaguchi, 750-0025, Japan. Email:
Cardiol Res. 2018 Jun;9(3):153-160. doi: 10.14740/cr733w. Epub 2018 Jun 6.
The reactive oxygen metabolites (d-ROMs) test has recently been explored as a novel marker of oxidative stress and used in clinical settings. Conversely, data regarding the utility of the d-ROMs test as a predictor of patients with chronic heart failure (CHF) are limited. This prospective study aims to elucidate the efficacy of the d-ROMs test as a predictor of initial heart failure (HF) hospitalization in elderly patients with CHF.
A total of 428 elderly outpatients with CHF with no history of HF hospitalization (108 males, 320 females; mean age, 75 ± 7 years) were enrolled. Based on the median value of d-ROMs test levels (303 U.CARR), the patients were divided into the following two groups: group L (low d-ROMs test levels) and group H (high d-ROMs test levels). The utility of the d-ROMs test as a predictor of initial HF hospitalization was evaluated.
During the 88.1-month follow-up period, 58 HF cases were hospitalized (group L, 17 cases; group H, 41 cases; P < 0.001, log-rank test). Multivariate Cox regression analyses revealed that group H exhibited a significantly higher risk for HF hospitalization than did group L (hazard ratio (HR), 2.35; 95% confidence interval (CI), 1.37 - 4.43; P < 0.01). Furthermore, the HR (vs. group L with low brain natriuretic peptide (BNP) levels (< 200 pg/mL), HR, 9.18; 95% CI, 4.78 - 22.94; P < 0.001) for the incidence of HF hospitalization increased in group H with high BNP levels (≥ 200 pg/mL).
The present study demonstrates that high d-ROMs test levels predict initial HF hospitalization in elderly patients with CHF. In addition, the predictive value for the incidence of HF hospitalization increases by using a combination of two biomarkers as d-ROMs test and BNP levels.
活性氧代谢产物(d-ROMs)检测最近被作为氧化应激的一种新标志物进行研究,并应用于临床。相反,关于d-ROMs检测作为慢性心力衰竭(CHF)患者预测指标的效用的数据有限。这项前瞻性研究旨在阐明d-ROMs检测作为老年CHF患者首次心力衰竭(HF)住院预测指标的有效性。
共纳入428例无HF住院史的老年CHF门诊患者(男性108例,女性320例;平均年龄75±7岁)。根据d-ROMs检测水平的中位数(303 U.CARR),将患者分为以下两组:L组(d-ROMs检测水平低)和H组(d-ROMs检测水平高)。评估d-ROMs检测作为首次HF住院预测指标的效用。
在88.1个月的随访期内,58例患者因HF住院(L组17例;H组41例;P<0.001,对数秩检验)。多因素Cox回归分析显示,H组HF住院风险显著高于L组(风险比(HR)为2.35;95%置信区间(CI)为1.37 - 4.43;P<0.01)。此外,高脑钠肽(BNP)水平(≥200 pg/mL)的H组HF住院发生率的HR(与低BNP水平(<200 pg/mL)的L组相比,HR为9.18;95%CI为4.78 - 22.94;P<0.001)升高。
本研究表明,高d-ROMs检测水平可预测老年CHF患者首次HF住院。此外,联合使用d-ROMs检测和BNP水平这两种生物标志物可提高HF住院发生率的预测价值。